- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.05. | Bullion Gold Resources Corp.: BULLION GOLD Confirms the Lateral Continuity of the LANGLADE Showing, Intersecting 41.0 m Grading 1.03% CuEq and 30.2 m Grading 0.95% CuEq | 287 | Newsfile | Montreal, Quebec--(Newsfile Corp. - May 5, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to announce assay results from the first two diamond drill holes... ► Artikel lesen | |
| 14.04. | Bullion Gold Resources Corp (2): Bullion Gold appoints Britt as president, CEO | 1 | Stockwatch | ||
| 13.04. | Bullion Gold Resources Corporation: Bullion Gold Announces the Appointment of Simon Britt as President and Chief Executive Officer | 373 | Newsfile | Montreal, Quebec--(Newsfile Corp. - April 13, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("the Company" or "Bullion") is pleased to announce the appointment of Mr. Simon Britt as President... ► Artikel lesen | |
| 10.04. | Bullion Gold Resources Corp (2): Bullion Gold completes diamond drilling at Langlade | 3 | Stockwatch | ||
| 09.04. | Bullion Gold Resources Corporation: Bullion Gold Completes Drilling Program on Langlade Project | 290 | Newsfile | Montreal, Quebec--(Newsfile Corp. - April 9, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce that it has successfully completed its diamond... ► Artikel lesen | |
| 31.03. | Bullion Gold Resources Corporation: 19.40m @ 17.29 g/t Au in Hole BO-26-63 at Bousquet | 406 | Newsfile | Montreal, Quebec--(Newsfile Corp. - March 31, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Corporation") and its partner Olympio Metals are pleased to announce the final... ► Artikel lesen | |
| 24.03. | Bullion Gold Resources Corp (2): Bullion Gold drills 7.5 m of 41.81 g/t Au at Bousquet | 2 | Stockwatch | ||
| 23.03. | Bullion Gold Resources Corporation: Bonanza Gold Intercept from Phase 2 Drilling at Bousquet | 517 | Newsfile | Montreal, Quebec--(Newsfile Corp. - March 23, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Corporation") is pleased to announce first assay results from the Phase 2 drilling... ► Artikel lesen | |
| BULLION GOLD RESOURCES Aktie jetzt für 0€ handeln | |||||
| 05.03. | Bullion Gold Resources Corp (2): Bullion Gold plans 25,000 m drill program at Terragold | 3 | Stockwatch | ||
| 05.03. | Bullion Gold Resources Corporation: Bullion Gold Plans a 25,000 M Drilling Program on Its Terragold Project | 462 | Newsfile | Montreal, Quebec--(Newsfile Corp. - March 5, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is currently preparing an application for a forestry intervention... ► Artikel lesen | |
| 26.02. | Bullion Gold Resources Corporation: Bullion Gold Obtains Drilling Permits for the Langlade Project | 417 | Newsfile | Montreal, Quebec--(Newsfile Corp. - February 26, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Corporation") announces that it has received approval from the Quebec Ministry... ► Artikel lesen | |
| 17.02. | Bullion Gold Resources Corporation: Diamond Drilling Intersects Multiple Visible Gold Occurrences at the Bousquet Gold Project | 590 | Newsfile | Montreal, Quebec--(Newsfile Corp. - February 17, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") and it's partner Olympio Metals are pleased to announce that the... ► Artikel lesen | |
| 13.02. | Bullion Gold Resources Corp (2): Bullion Gold restarts drilling at Bousquet project | 1 | Stockwatch | ||
| 12.02. | Bullion Gold Resources Corporation: Drilling Resumes at Bousquet Gold Project, Quebec | 351 | Newsfile | Montréal, Québec--(Newsfile Corp. - February 12, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce that it's partner Olympio Metals ("Olympio")... ► Artikel lesen | |
| 12.02. | XFRA NEW INSTRUMENTS AVAILABLE ON 12.02.2026 | 460 | Xetra Newsboard | The following instruments on XETRA do have their first trading 12.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 12.02.2026
Aktien
1 CA13723D1006 Canasil Resources Inc.
2... ► Artikel lesen | |
| 03.02. | Bullion Gold Resources Corp (2): Bullion Gold acquisition of Abitibi mining claims | 1 | Stockwatch | ||
| 27.01. | Bullion Gold Resources Corp (2): Bullion Gold takes 100% ownership of Terragold | 2 | Stockwatch | ||
| 26.01. | Bullion Gold Resources Corporation: Bullion Gold Acquires 100% of the Terragold Project and Consolidates a Strategic Gold Asset | 338 | Newsfile | Montreal, Quebec--(Newsfile Corp. - January 26, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce the signing of an amendment to the original... ► Artikel lesen | |
| 09.01. | Bullion Gold Resources Corp (2): Bullion Gold private placement | 2 | Stockwatch | ||
| 06.01. | Bullion Gold Resources Corporation: High-Grade Gold up to 12.2 g/t Intersected in Multiple Structures at Bousquet | 596 | Newsfile | Montreal, Quebec--(Newsfile Corp. - January 6, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Corporation") is pleased to announce further assay results for the Bousquet... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INHIBRX BIOSCIENCES | 109,03 | +0,35 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 12,150 | +1,17 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,62 | +0,12 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| CG ONCOLOGY | 72,05 | -0,03 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,400 | -0,12 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 16,140 | -0,06 % | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | ||
| ARCUTIS BIOTHERAPEUTICS | 20,700 | +0,05 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| ERASCA | 10,390 | +0,10 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| NUVALENT | 102,64 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| EVOTEC | 4,648 | -8,50 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,960 | +0,05 % | H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk | ||
| COGENT BIOSCIENCES | 34,530 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| ANNEXON | 5,440 | 0,00 % | Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 18,200 | +0,06 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results | MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 42,260 | -0,09 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Phase 1 data update for ELVN-001 expected mid-2026
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026
Strong balance... ► Artikel lesen |
BULLION GOLD RESOURCES CORPORATION gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BULLION GOLD RESOURCES CORPORATION finden Sie auf Wallstreet Online.